Our global list of drug combinations
The following is a list of products listed by our company, which is only for medical professionals to refer to.
EPIAO （Human Erythropoietin Injection)
In 1998, EPIAO was marketed with approval of the NMPA, which was the first rhEPO products marketed in China. Since 2002, it has been the leading brand of China’s erythropoin market. It is included in the National Medical Insurance Catalogue as a Category B drug. Athletes should be careful to use it
| Indication | Manufacturing base | Dosage form & Dosage |
|
Treatment for anemia caused by chronic kidney disease; Erythrocyte mobilization of peripheral operation; Treatment for anemia caused by chemotherapy. |
Shenyang manufacturing base |
Penicillin bottle - 2,000 IU/piece, 3,000 IU/piece, 4,000 IU/piece, 10,000 IU/piece, 36,000 IU/piece; Pre-filled syringe - 2,000 IU/piece, 3,000 IU/piece, 4,000 IU/piece, 10,000 IU/piece. |
SEPO （Human Erythropoietin Injection)
NMPA production approval documents were obtained for SEPO in 2001. It was listed in 2002 and is included in the National Medical Insurance Catalogue as a Category B drug. In 2014, SEPO was rated as famous trademark by Guangdong Province Administration for Industry & Commerce. Athletes should be careful to use it
| Indication | Manufacturing base | Dosage form & Dosage |
|
Treatment for anemia caused by chronic kidney disease; Treatment for anemia caused by chemotherapy. |
Shenzhen manufacturing base |
Penicillin bottle - 2000IU/1.0ml/piece, 2500IU/1.0ml/piece, 3000IU/1.0ml/piece, 4000IU/1.0ml/piece, 5000IU/1.0ml/piece, 10000IU/1.0ml/piece; Pre-filled syringe - 2000IU/0.5ml/piece, 2500IU/0.5ml/piece, 3000IU/0.5ml/piece, 4000IU/0.5ml/piece, 5000IU/0.5ml/piece, 10000IU/0.5ml/piece (PFS). |
SPARIN （Injectable low-molecular-weight heparin calcium (LMWH-Ca))
SPARIN was approved by the NMPA and listed in 2002. Low-molecular-weight heparin calcium is derived from depolymerization of standard heparin. Compared to standard heparin, low-molecular-weight heparin calcium has the advantages of lower side effects and more predictable anticoagulant response.
| Indication | Manufacturing base | Dosage form & Dosage |
|
The product is used for prophylaxis and treatment of deep vein thrombosis and prevention of clotting during hemodialysis. |
Shenzhen manufacturing base | / |
Xenopax （Recombinant humanized anti-CD25 monoclonal antibody injection)
Xenopax is suitable for prevention of acute rejection after renal transplantation, which can be combined with the routine immunosuppression regime to significantly improve the survival rate of transplanted organs and the quality of life of patients.
| Indication | Manufacturing base | Dosage form & Dosage |
|
The product is suitable for prevention of acute rejection after renal transplantation, which can be combined with the immunosuppression regime containing calcineurin inhibitors and corticosteroid hormone. |
Shanghai manufacturing base | 25mg/5ml/vial |